Introduction: With 36 million older adult U.S. drivers, safety is a critical concern, particularly among those with dementia. It is unclear at what stage of Alzheimer's disease (AD) older adults stop driving and whether preclinical AD affects driving cessation. Methods: Time to driving cessation was examined based on Clinical Dementia Rating (CDR) and AD cerebrospinal fluid biomarkers. 1795 older adults followed up to 24 years received CDR ratings. A subset (591) had cerebrospinal fluid biomarker measurements and was followed up to 17 years. Differences in CDR and biomarker groups as predictors of time to driving cessation were analyzed using Kaplan-Meier curves and Cox proportional models. Results: Higher CDR scores and more abnormal biomarker measurements predicted a shorter time to driving cessation. Discussion: Higher levels of AD biomarkers, including among individuals with preclinical AD, lead to earlier driving cessation. Negative functional outcomes of preclinical AD show a nonbenign phase of the disease.

Original languageEnglish
Pages (from-to)610-616
Number of pages7
JournalAlzheimer's and Dementia
Issue number5
StatePublished - May 2018


  • Aged
  • Alzheimer's disease
  • Amyloid β
  • Biomarker
  • Cerebrospinal fluid
  • Driving
  • Driving cessation
  • Older adults
  • Preclinical
  • Tau
  • ptau


Dive into the research topics of 'Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers'. Together they form a unique fingerprint.

Cite this